REGNRegeneron PharmaceuticalsSigning up patients
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Non Small Cell Lung Cancer · Advanced Non Small Cell Lung Cancer · Metastatic Non Small Cell Lung Cancer · Carcinoma Non Small Cell Lung
5Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.8
5 insiders sold shares within a month
Since Nov 4, 2026 · was worth 5, fading over time
Worry score5
Score over time
- Stage
- Phase 2
- Patients
- 300 (planned)
- Started
- Mar 18, 2026
- Main results expected
- Jun 10, 2030
- Fully finished
- Jun 10, 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective response as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Measured over: Up to 5 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 4.8, since 2026-11-04, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07154290 · record last updated 2026-10-22 · checked 2026-11-09 15:47 UTC